RGT 5.17% 30.5¢ argent biopharma limited

Christmas, page-25

  1. 2,484 Posts.
    lightbulb Created with Sketch. 80

    The Company was recently awarded a full Good Manufacturing Practice (GMP) licence for its European Production and Manufacturing facility in Slovenia, following production of its first commercial batch of epilepsy medicine, CannEpil™. Receipt of this certification has advanced MGC Pharma towards the final stages for commercialisation which will follow the completion of final tests, CannEpilTM becoming available for supply in Australia under the Authorised Prescriber Scheme by the TGA, and its final validation.


    Source



 
watchlist Created with Sketch. Add RGT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.